The way in which an antibiotic interacts with host defences could influence the clinical outcome of many infectious diseases. The impact of RO 23-9424, a novel dual-action and extended-spectrum antibiotic, was studied on several functions of human polymorphonuclear neutrophils (PMNs). A significant (P < 0.05) increase of the superoxide 
Introduction
Infections by bacteria as well as fungi remain an important clinical problem in immunocompetent patients and are more difficult to treat in immunocompromised patients, where the antibiotic of choice should have a potent antimicrobial effect without impairing host defences, such as functions of polymorphonuclear neutrophils (PMNs) and mononuclear phagocytes (Gemmell, 1993) .
RO 23-9424 is a novel antibacterial agent, in which the microbiologically active metabolite of cefotaxime, desacetylcefotaxime, has been linked by an ester bond at the C-3 position to the carboxy group of the long-acting quinolone fleroxacin (Georgopapadakou et al., 1989) . It has been reported to be a potent, broad-spectrum antibiotic, which has activity against /Mactamase-producing organisms because of the quinolone moiety and provides an activity against streptococci due to the cephalosporin moiety (Rolston et al., 1992) .
The aim of the present study was to characterize the influence of RO 23-9424 and its two different components on PMN functions (phagocytosis and killing of Candida albicans, chemotaxis, and production of superoxide anion) over a broad range of concentrations. The effects of these antibiotics on the release of tumour necrosis factor-a (TNF-a), interleukin-1/? (IL-1/?), and interleukin-8 (IL-8) from monocytes, both in basal conditions and after bacterial lipopolysaccharide (LPS) stimulation were also evaluated.
Materials and methods

Antibiotics
RO 23-9424 (Roche, Nutley, USA), fleroxacin (Roche, Milan, Italy) and cefotaxime (Hoechst, Milan, Italy) were dissolved in sterile pyrogen-free saline immediately before use.
PMN isolation
Heparinized venous blood was collected from healthy volunteers and combined with two volumes of 3% dextran (molecular weight 264,000; Sigma, Italy) in sterile saline. After 20 min of spontaneous sedimentation of red blood cells at room temperature, PMNs were isolated by plasma separation of Ficoll-Paque (Pharmacia Biotech, Milan, Italy) gradient. Contaminating erythrocytes were lysed by suspension of the neutrophil pellet in distilled H 2 O for 15-20 sec, followed by the addition of hypertonic saline to correct hypotonicity of the solution. PMNs were washed and resuspended in RPMI medium.
Phagocytosis and intracellular killing
Phagocytosis and intracellular killing of C. albicans by PMNs were evaluated using a micromethod based on vital staining of ingested yeasts with acridine orange (Smith & Rommel, 1977) . After adhesion to Petri dishes, the cells (1 x 10 6 cells/dish) were incubated for 1 h with different concentrations of the antibiotics (5-10-20-50-100-200 mg/L), then washed and incubated for 1 h with an opsonized C. albicans suspension (5 x 10 5 yeasts/mL). The Petri dishes were washed twice with RPMI to eliminate the unphagocytosed yeasts. Cells were then stained with an acridine orange solution (1.44 g/L). A differential count of cells containing yeasts was performed and phagocytosis was expressed as the percentage of PMNs which ingested yeasts per counted cells, while the intracellular killing activity was expressed as the percentage of PMNs containing dead yeasts per phagocytising cells. At least 200 phagocytes were scored on each dish and all the experiments were carried out in duplicate. C. albicans was used for this study on an antibacterial drug in order to separate the killing activity due to phagocytes from the microbicidal effect caused by antibiotic.
Chemotaxis (leading front)
The influence of the drug on locomation of PMNs was studied by activating human serum with 1 g/L of Escherichia coli endotoxin. Activated serum was diluted to 30% in RPMI 1640 and put in the lower compartment of the Boyden chamber. Millipore filters (3/im pore size) were used. Suspensions of cells (2 x lO'/mL) were separately incubated with the antibiotics at different concentrations for 1 h, then the cells were added to the upper compartments of the chamber. After 60 min of incubation, the filters were fixed and stained following the standard procedures (Maderazo & Waronick, 1978) .
The distance migrated (jim) by the leading front (LF) of the cells was measured according to a previously published technique (Maderazo & Waronick, 1978) .
Release of O 2~ was detected spectrophotometrically by superoxide dismutase-inhibitable reduction of cytochrome C (type III, Sigma). This assay was performed as originally described by Johnston, Godjik & Cohn (1978) with modifications. The mixture contained 80 /iM of cytochrome C and 130 U of superoxide dismutase (SOD, Sigma). A volume of 10 fiL of phorbol-myristate acetate (PMA, Sigma) from a stock solution of 5 mg/L was then added to the mixture (final concentration 50 ng/plate, or 33 /ig/L) as stimulating agent. PMNs (1 x 10 6 cells/mL) that had been either untreated, or Of release (nmoles/10 6 PMN) unstimulated 5.6 ± 1.0 4.7 ±0.7 5.5 ± 0.4 6.3 ± 0.4 4.6 ± 0.5 4.1 ±0.6 4.1 ±0.4 8.9 ± 0.7 8.8 ± 0.6 6.6 ±0.9* 7.2 ± 0.6* 7.2 ±0.1* 7.4 ± 0.5* 6.6 ± 0.4* 6.2+1.1 6.4 ± 1.2 7.1 ± 1.1 8.5 ± 1.1 8.1 ± 1.5 9.2 ± 0.6 8. pretreated with antibiotics, at different concentrations, for 1 h, were incubated with the mixture at 37°C for 15 min. The reduction of cytochrome C was measured at 550 nm with a reference wavelength of 468 nm.
Cytokine production and immunoassay
Following adherence the monocytes were washed and microscopy showed that the number of monocytes per dish was approximately 10' and 2 mL of RPMI medium was added to monolayers. Such a medium was supplemented with 1 % heat inactivated fetal calf serum and contained 10 mg/L of LPS of Salmonella minnesota R595 (Calbiochem, La Jolla, USA), with or without antibiotic (100-200 mg/L). Cultures were incubated for 4 and 24 h at 37°C in 5% CO 2 . To determine extracellular cytokine concentrations, cell-free supernatants were collected, centrifuged at 800 g for 10 min, and stored at -70°C until assay. Cytokine concentrations were measured by commercially available enzyme-linked immunosorbent assay (ELISA) (Amersham, Milan, Italy) , following the quantitative immunometric sandwich ELISA technique.
The lower limit of sensitivity of the assays for TNF-a, IL-1/?, and IL-8 were 4.4, 0.30 and 4.7 ng/L respectively. No cross-reactivity or interference among the above reported cytokines was found.
Statistical analysis of data
Data are reported as means ± S.E.M. unless otherwise specified. Results were examined by analysis of variance and significant differences between experimental groups and were determined by means of the Fisher's protected least square difference test (PLSD test). A P 0.05 was considered significant.
Results
PMN functions
The effect of RO 23-9424 and cefotaxime on the phagocytic activity of PMN followed a peculiar trend (NS) observed as an increase of such functions at the lower concentrations (5 and 10 mg/L) but no change at the higher dosages. Fleroxacin did not interfere with phagocytic function of PMNs. All three drugs had no effect on the killing of C. albicans cells. Both (Table II) .
Cytokine release by monocytes
Effects of RO 23-9424 on the release of TNF-a, IL-10 and IL-8 are shown in Table III and indicates a substantial increase of cytokine concentrations in cell culture media following monocyte challenge by LPS.
In (Table IV) and reduced basal and LPS-induced increase of IL-8 in culture media after 200 mg/L and 100 mg/L of cefotaxime respectively. Fleroxacin (100 mg/L) significantly elevated the IL-8 levels after 24 h of incubation (Table V) .
Discussion
Increasing experimental efforts are beginning to shed light on the effects of antibiotic classes on phagocytic cell functions (Foca et al., 1991; Gemmell, 1993; Matera, Berlinghieri & Foca, 1995) . However, data reported by various groups of investigators are often quite difficult to compare due to major differences in experimental protocols. RO 23-9424 offers an interesting opportunity in this field because its structure includes a quinolone (fleroxacin) moiety beside a /?-lactam (desacetylcefotaxime). Some third generation cephalosporins, including cefotaxime, have been reported to function as biological response modifiers (Gillissen & Melzer, 1985; Gemmell, 1993; Osaki et al., 1993) . Quinolones, unlike /?-lactams, are well known to achieve a very high intracellular concentration. One of the aims of the present study was to characterize the influence of RO 23-9424 and its two different components on PMN functions over a broad range of concentrations. The other aim was to address the effects of RO 23-9424 on the production of cytokines by monocytes.
During preliminary experiments with these agents and the very small amount of desacetylcefotaxime available to us, we found no significant differences between the effects of cefotaxime and desacetylcefotaxime. This is in keeping with previous in-vitro (Beskid et al., 1989) and in-vivo (Beskid et al., 1990 ) studies which selected cefotaxime instead of its desacetyl derivative as the comparative agent closest to the /?-lactam component of this dual action antibiotic.
RO 23-9424, particularly at low dosages, showed an interesting and potentially useful, although not statistically significant, effect on phagocytosis by PMN. Moreover, the increase of O 2~ release, in RO 23-9424-treated PMN may suggest an helpful effect of such antibiotic, with an eventual increase of bactericidal potential of the human PMA-stimulated PMN. This is similar to the situation that may happen in-vivo when bacterial products (e.g. LPS, teichoic acid) act on PMN together with the antibiotic. However, to explain the inconsistency that may appear between the lack of any effect of RO 23-9424 on killing and the strong and significant increase of PMA-stimulated superoxide release by PMN, one should take into account the technical differences of those two models and the major role of oxygen-independent mechanisms in PMN fungicidal activity (Boman, 1995) . Labro et al. (1987) reported that cefotaxime, over a broad range of concentrations (up to 100 mg/L), did not change PMN phagocytosis of bacterial cells measured by the acridine orange method. These data are consistent with our results. In the same experiment Labro et al. (1987) also demonstrated an oxygen-dependent cefotaximestimulated enhancement of the PMN killing activity. Our finding of unmodified killing by cefotaxime may be explained by taking in account the technical differences of the two models such as the direct antibiotic effect on PMN killing function is easier to assess using yeasts rather than bacteria and the major role of oxygen-independent mechanisms in PMN fungicidal activity (Boman, 1995) .
Cefotaxime has previously been reported to enhance the oxidative response of PMN to opsonized particulate stimuli whereas the lack of opsonization and a soluble stimulus (e.g. PMA or FMLP) did not result in an increased oxidative burst, regardless of the technique used to evaluate PMN response (Labro, Babin-Chevaye & Hakim, 1986; Labro et al., 1987; Labro & El Benna, 1991) . In our experiments on superoxide release neither an opsonization procedure nor a particulate stimulus were used, thus explaining the apparent inconsistence. Furthermore, Labro & El Benna (1991) reported that aminothiazolyl cephalosporins, including cefotaxime, showed different effects on the neutrophil functions depending on the substituent in position 3 of the cephem nucleus. Accordingly the whole molecule of RO 23-9424 may be considered as an aminothiazolyl cephalosporin, with a quinolone substituent in position 3. Such a substituent may account for the peculiar effects of RO 23-9424 on some PMN functions, particularly superoxide production.
Quinolones including fleroxacin have been reported to show little direct effect on PMN functions in concentrations ranging from 0.1 to 50 mg/L (Shalit, 1991) . The increase of killing reported by Forsgren & Bergkvist (1985) seems due to bacterial cell alterations, which may favour the ingestive behavior of PMN. Our data on the lack of any fleroxacin-stimulated phagocytosis and killing (using up to 200 mg/L of drug) are in agreement with these papers. The quinolones, unlike /?-lactam antibiotics, may reach very high intracellular concentration, and a synergistic interaction between oxygen-dependent mechanisms and ciprofloxacin antibacterial effect has been shown by Peman et al. (1994) pointing to an indirect effect of quinolones on phagocyte antimicrobial functions. However, van Rensburg, Joone & Anderson (1990) showed that fleroxacin was a less effective antimicrobial within PMNs obtained from patients with chronic granulomatous disease. Although we know that oxygen-dependent systems of PMN are impaired in such patients and could not support the favourable synergic interaction with this agent, our results on reduced superoxide release from unstimulated normal PMN, in presence of a broad range (10-200 mg/L) of fleroxacin concentrations, may offer a further explanation for the difficult eradication of intraphagocytic microbes in PMN from immunocompromised patients treated with fleroxacin.
To our knowledge there are no data dealing with the effects of RO 23-9424 on cytokine release although our findings suggest a general trend towards an increase of TNF-a, a reduction of IL-1/? and a lack of any significant effect on IL-8 release. Moreover, cefotaxime appeared to increase IL-1/? and reduce 11-8, while fleroxacin enhanced IL-8 concentrations. Accordingly, other investigators reported that cefixime has been observed to stimulate II-1/? release in murine macrophages cultures (Gillissen & Melzer, 1985) .
The effect of ciprofloxacin and other quinolones (25 mg/kg, orally) on LPS-induced IL-1/? and TNFa release has been studied in vitro and ex vivo. The latter experiments revealed an increased production of the investigated cytokines whereas in-vitro tests, using antibiotic concentrations higher than 25 mg/L (Bailly et al., 1991; Bailly, Fay & Gougerot-Pocidalo, 1993) , showed a reduction of IL-1/? and TNF-a release. The significantly higher dosage used in-vitro may explain the apparent differences.
The mechanism behind selective inhibition of IL-1 /? is thought to involve a post-transcriptional step as intracellular levels of IL-1/? remained unchanged (Bailly et al., 1990) .
Thus, it could be argued that the dangerous systemic effects of IL-1 /? during sepsis and other severe inflammatory reactions (e.g. haemodynamic impairment and tissue injury) may be controlled without affecting the positive local (juxtacrine) immune effects and the many anti-infective actions of IL-1/? (Glauser, 1994) . Furthermore, the host toxicity of TNF-a is specifically enhanced by the contemporary increase of IL-1/? (Glauser, 1994) and by the release of microbial products (e.g. LPS, lipoteicoic acid) during severe systemic sepsis and following the use of potent bactericidal antibiotics, such as /?-lactams and quinolones.
Our data suggest that RO 23-9424 appears to increase superoxide production by PMA-stimulated PMN and enhance LPS-induced TNF-a release with a decrease of IL-1/? levels which may be helpful for the defense of the host against microbial pathogens, without initiating an increasing and self-maintaining cascade of dangerous inflammatory systemic reactions. In conclusion the interesting properties of RO 23-9424, as a biological response modifier merit further investigation.
